Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 12/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | RAF1 | P04049 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MERTK | Q12866 | 1/20 | 0.42 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14920998 | 0.86 | MAPK1 (0.56) | VCAM1MAPK1ALDH1A1LMNARAF1 | |
| SCHEMBL1318602 | 0.83 | ALDH1A1 (0.50) | MAPK1ALDH1A1LMNAMAPTTDP1 | |
| SCHEMBL12903344 | 0.81 | VCAM1 (0.53) | VCAM1MAPK1ALDH1A1LMNARAF1 | |
| SCHEMBL541479 | 0.80 | ALDH1A1 (0.68) | VCAM1MAPK1ALDH1A1LMNARAF1 | |
| SCHEMBL31362162 | 0.80 | VCAM1 (0.51) | VCAM1MAPK1ALDH1A1LMNARAF1 | |
| SCHEMBL177217 | 0.79 | ALDH1A1 (0.53) | MAPK1ALDH1A1LMNAMAPTHPGD | |
| SCHEMBL15591962 | 0.77 | VCAM1 (0.57) | VCAM1MAPK1ALDH1A1LMNARAF1 | |
| SCHEMBL8755086 | 0.77 | MAPT (0.49) | VCAM1MAPK1ALDH1A1LMNARAF1 | |
| SCHEMBL9734010 | 0.76 | VCAM1 (0.54) | VCAM1MAPK1ALDH1A1LMNARAF1 | |
| SCHEMBL1128959 | 0.76 | VCAM1 (0.53) | VCAM1MAPK1ALDH1A1LMNARAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1993016195-A1 | CHEMILUMINESCENT ENHANCERS | BRITISH TECHNOLOGY GROUP LTD. (GB) | 1993-08-19 | — | — | WO | claimed |
| EP-3360869-B1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND USEFUL FOR THE TREATMENT OF DISEASES CAUSED BY LPA. | UBE INDUSTRIES (JP) | 2020-07-29 | — | — | EP | disclosed |
| US-10597375-B2 | Halogen-substituted heterocyclic compound | UBE INDUSTRIES, LTD. (JP) | 2020-03-24 | — | — | US | disclosed |
| EP-3243515-B1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20180258062-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2018-09-13 | — | — | US | disclosed |
| US-10000463-B2 | Halogen-substituted heterocyclic compound | UBE INDUSTRIES, LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| US-9981918-B2 | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2018-05-29 | — | — | US | disclosed |
| EP-2940013-B1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | UBE INDUSTRIES (JP) | 2018-02-21 | — | — | EP | disclosed |
| EP-3243515-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI Foundation, Inc. (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2750677-B1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2017-03-22 | — | — | EP | disclosed |
| US-20160251318-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2016-09-01 | — | — | US | disclosed |
| US-20150376160-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2015-12-31 | — | — | US | disclosed |
| EP-2940013-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | UBE Industries, Ltd. (JP) | 2015-11-04 | — | — | EP | disclosed |
| EP-2750677-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI Foundation, Inc. (US) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013033085-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | COURTNEY STEPHEN MARTIN (GB) | 2013-03-07 | — | — | WO | disclosed |
| WO-1994023060-A2 | ENHANCEMENT OF CHEMILUMINESCENT REACTIONS | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1994-10-13 | — | — | WO | disclosed |
| WO-1993016195-A1 | CHEMILUMINESCENT ENHANCERS | BRITISH TECHNOLOGY GROUP LTD. (GB) | 1993-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376160-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | LPAR3, LPAR1, LPAR2 | VCAM1 1860/4885MAPK1 932/4885ALDH1A1 1997/4885 |
| US-10000463-B2 | Halogen-substituted heterocyclic compound | LPAR1, LPAR4, LPAR2 | VCAM1 1657/4885MAPK1 1426/4885ALDH1A1 1964/4885 |
| US-20160251318-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, HAAO | VCAM1 3487/4885MAPK1 1903/4885ALDH1A1 1261/4885 |
| US-20180258062-A1 | HALOGEN-SUBSTITUTED HETEROCYCLIC COMPOUND | LPAR3, LPAR1, LPAR2 | VCAM1 1860/4885MAPK1 932/4885ALDH1A1 1997/4885 |
| US-10597375-B2 | Halogen-substituted heterocyclic compound | LPAR3, LPAR1, LPAR2 | VCAM1 1860/4885MAPK1 932/4885ALDH1A1 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.